Safety and efficacy of adalimumab in patients with moderate to severe hidradenitis suppurativa: Results from first 12 weeks of PIONEER I, a phase 3, randomized, placebo-controlled trial - 09/05/15
Alexa Kimball, Harvard Medical School, Boston, MA, United States; Christos Zouboulis, Departments of Dermatology, Venereology, Allergology and Immunology, Dessau, Germany; April Armstrong, University of Colorado, Denver, CO, United States; Neil Korman, University Hospitals (UH) Case Medical Center, Cleveland, OH, United States; Jeffrey Crowley, Bakersfield Dermatology, Bakersfield, CA, United States; Charles Lynde, The Lynde Center for Dermatology, Markham, Ontario, Canada; Kimberly Belknap, AbbVie Inc, North Chicago, IL, United States; Yihua Gu, AbbVie Inc, North Chicago, IL, United States; David Williams, AbbVie Inc, North Chicago, IL, United States
Le texte complet de cet article est disponible en PDF.| AbbVie In. participated in the study design; study research; collection, analysis and interpretation of data; and writing, reviewing and approving of this publication. All authors had access to the data, and participated in the development, review, and approval, and in the decision to submit this publication. AbbVie funded the research for this study and provided writing support for this abstract. Jody Bennett, employed by AbbVie, provided medical writing support. |
Vol 72 - N° 5S1
P. AB60 - mai 2015 Retour au numéro
Article précédent
- Recalcitrant rashes during pregnancy: An atypical presentation of drug-induced cutaneous lupus erythematous (DIL) from hypertension management
- Safety of use of high dose antihistamines in difficult-to-control chronic urticaria patients
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?